Company Analysis

Tango Therapeutics, Inc. (TNGX)

Nasdaq: TNGX · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2020
Grade5.6
◀ Past 6.2● Present 5.6▶ Future 5.2
1 est.

Who runs Tango Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Peters Malte
President & CEO. First filing Aug 2021, latest Jan 12, 2026, 0 filings in all.
Officers reporting now
6
of 11 people with a filing in the last fifteen months
Directors reporting now
5
34 people on the record since 2020
Officerssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Crystal AdamPresident, R&DMar 2023Nov 4, 202620 · $7.1M
Newcomb JessicaPrincipal Accounting OfficerApr 2026Nov 4, 20265 · $400,000
Gall MatthewChief Financial OfficerApr 2026May 5, 2026none
Weber BarbaraDirector, Executive ChairAug 2021Feb 4, 20262 · $400,000
Beckman DaniellaChief Financial OfficerAug 2021Feb 4, 20262 · $100,000
Peters MaltePresident & CEOAug 2021Jan 12, 2026none
Directorssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameRoleFirst filingLatest filingSales, 12 months
Azelby RobertdirectorJun 2026Jun 23, 2026none
Calhoun Lesley AnndirectorAug 2021Jun 8, 2026none
Ketchum John BdirectorAug 2023Jun 8, 2026none
Lee SungdirectorJan 2026Jun 8, 2026none
Rothenberg MacedirectorAug 2021Jun 8, 2026none
Owners of more than 10% of a classsales are open-market, Nov 4, 2025 to Nov 4, 2026
NameRoleFirst filingLatest filingSales, 12 months
Third Rock Ventures Gp IV, L.P.10% ownerAug 2021Oct 27, 2025none
Third Rock Ventures IV, L.P.10% ownerAug 2021Oct 27, 2025none
Trv Gp IV, LLC10% ownerAug 2021Oct 27, 2025none
Earlier names on the record27, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton TNGX · research, not advice